New #MerkelCellCarcinoma data at #ASCO26, presented by Janice Mehnert, MD: While relapse-free survival did not meet statistical significance, adjuvant pembro significantly reduced distant spread—an important clinical signal in this rare cancer. More: bit.ly/3PxCeOU #SkinCancer

New insights from #ASCO26 Day 4 continue to shape the #oncology landscape—including updates from @eaonc.bsky.social studies in #NSCLC (EA5142/ALCHEMIST), and #MerkelCellCarcinoma (EA6174/STAMP). Helpful podcast summary for a quick download: bit.ly/4uRmiX8

Sustained #CancerResearch funding fuels progress. Progress saves lives. @ascocancer.bsky.social is urging Congress to protect cancer research funding in FY27. Read the full statement: bit.ly/4v1rnM9 #NIH #HealthPolicy

The #EAOnc Spring 2026 Group Meeting officially begins today! Looking forward to seeing you in Baltimore. Check in at the registration desk on the 4th floor before heading to your first session. 🩺🩻📈

#FindingsFriday: Don’t miss the newest round-up of recently published findings from @eaonc.bsky.social #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/4ed3xb6

Early onset #ColorectalCancer is rising. Genetics explain only part of it. @npr.org explores how the #GutMicrobiome may be a missing piece—highlighting the necessity of initiatives like our Microbiome Working Group: bit.ly/4uaZCQH

Attending our Spring 2026 Group Meeting next week? Don't miss the Comis Symposium (5/5 @ noon), focused on 'Susceptibility and Inflammation,' or the General Session (5/6 @ 9 am), ft. cutting-edge cancer vaccine development strategies. Read more: bit.ly/4vVjU2f

#FindingsFriday: A new study using data from the E2993 #ClinicalTrial uncovers how acute #leukemia cells stabilize oncogenic tyrosine kinase signaling through dynamic feedback control—offering fresh targets for therapy. Read more in @science.org: bit.ly/4cUmWfJ

What did the PROSPER trial teach us about neoadjuvant therapy in #RenalCellCarcinoma—and what questions still remain? Our GU #Cancer Committee Chair Dr. Naomi Haas shares lessons learned and practical considerations: bit.ly/4vsG8Zd #KidneyCancer #RCC

Attending #AACR26 next week and interested in #RealWorldEvidence and #ClinicalTrial design? Don't miss Session MW04: Clinical Trial Design Workshop chaired by @eaonc.bsky.social Group Co Chair Dr. Peter O'Dwyer 🗓 Apr 17 | 3–4:30 PM | Room 31 #RWE #CancerResearch

Proposed #NIH funding cuts and grant changes in the FY 2027 budget request could significantly slow progress in #CancerResearch—and ultimately impact patients. Read more via @ascocancer.bsky.social: bit.ly/4e6TX9p

📊 How can #RealWorldData strengthen cancer #ClinicalTrial design? At #AACR26, join Session MW04: Clinical Trial Design Workshop – #RealWorldEvidence in Clinical Trial Design, chaired by @eaonc.bsky.social Group Co Chair Dr. Peter O'Dwyer🗓 Apr 17 | 3–4:30 PM | Room 31 #RWE #CancerResearch

Early treatment for high risk #SmolderingMyeloma is no longer hypothetical—it’s FDA approved. Now #ClinicalTrials like EAA173 (DETER SMM) are critical to determine who benefits most and how much treatment is enough. Learn more about #SMM: bit.ly/4bVbJdk #MultipleMyeloma

New video: Dr. Monika Joshi & @pgrivasmdphd.bsky.social discuss the EA8231 #ClinicalTrial, which aims to evaluate and answer the critical question of #immunotherapy (anti-PD1/L1) rechallenge in #UrothelialCancer therapy. Watch here: bit.ly/47UxFnr #BladderCancer

At #SSO2026 in early March, Dr. Maheswari Senthil presented results from the phase 2 STOPGAP trial for patients with #GastricCancer. This study laid the groundwork for ECOG-ACRIN Cancer Research Group's STOPGAP II, currently enrolling patients! More: bit.ly/47Bhbk1

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. bit.ly/ea8192-trial

New data show #NIH research grant success rates plummeted in 2025—falling to around ~19–20% overall & hitting early-career scientists especially hard. The ripple effects could shape the biomedical workforce for years. More: bit.ly/46PsJjq #ResearchFunding #SciencePolicy

#FindingsFriday: ICYMI, new data from @precogonc.bsky.social PrE0405, presented at #ASH25, showed that treatment with BR-VEN led to high response rates & promising CR rates for older patients w/ mantle cell #lymphoma. More: bit.ly/4aReE69 #MCL

Debate continues: should #immunotherapy move earlier in undifferentiated pleomorphic #sarcoma ( #UPS ) care? Insights from Dr. Seth Pollack and the ECOG-ACRIN EA7222 trial shed light on evolving treatment paradigms. Watch the video: bit.ly/3OVL3ky

‼️ New #ComboMATCH updates are enhancing patient care: ctDNA-based screening and progression biopsy results returned to treating physicians to inform future treatment decisions, advancing #PrecisionOncology for patients with specific DNA alterations. More ➡️ bit.ly/46Vdbug

In the @washingtonpost.com, Dr. Leana Wen argues for more personalized #BreastCancer screening—moving beyond 1-size-fits-all mammograms. That’s exactly what our #TMIST trial is evaluating: how 3D tomo compares to standard mammography & who benefits most. More: bit.ly/4rYQHRf

Trial Activation: EA6232, led by Dr. John Kirkwood of UPMC, is a phase II double-blind trial of sulforaphane for therapeutic prevention of #Melanoma in patients with multiple atypical nevi and a prior history of melanoma. Learn more: bit.ly/EA6232

We’re headed back to Baltimore! The ECOG-ACRIN Spring 2026 Group Meeting will be held May 5–7, 2026 (Tues–Thurs, note the shift from Wed–Fri). Join us in Baltimore for plenary sessions, networking, and collaboration. Stay tuned for registration details. #EAOnc

On #WorldCancerDay, we thank the patients, advocates, clinicians, and research teams who make ECOG-ACRIN trials possible. Your participation drives discovery and delivers hope. #CancerCare #UnitedByUnique

Fellows: Apply by 2/19 for the 2026 Paul Carbone, MD Fellowship Award, a research grant for senior oncology or hematology fellows that aims to develop & promote excellence in #clinicaltrials. Learn more: bit.ly/ea-carbone #cancerresearch

EA1241, led by Dr. Joseph Sparano of The Mount Sinai Hospital, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: bit.ly/EA1241

The nomination period is now open for the 2026 @eaonc.bsky.social Young Investigator Award! 🩺 This honor recognizes the scientific achievements of early-career investigators. Learn more & nominate a colleague by 2/19: bit.ly/ea-yia #mentorship #CancerResearch #ClinicalTrials

#Cancer #survivorship is up—but sustained research funding and equitable access to screening & treatment are key to continued progress. Learn more via ABC News: bit.ly/3NvFTv0 #CancerPolicy #CancerResearch

EA is hosting a webinar on EA1241, a companion study for pts previously enrolled in TAILORx or RxPONDER. Investigators & #ClinicalResearch professionals are invited to register below. 📅Feb 4 | 4 PM ET 🎙 Joseph Sparano, MD, Kevin Kalinsky, MD, MS, & Rima Patel, MD 🔗https://bit.ly/EA1241webinar

DYK funding for NIH and NCI ends on 1/30? Act now & ask Congress to support sustainable, long-term funding for biomedical & #CancerResearch for FY26: bit.ly/3LpZJau

“This is a great time to be in hashtag#oncology” — and also a time to rebuild how we support hashtag#science, access, & policy, says Dr. Otis Brawley, chair of our Social Determinants of Health Working Group. Catch his reflections in The Cancer Letter: bit.ly/4pgVzPX #SciencePolicy #SDOH

#FindingsFriday: Don’t miss the newest round-up of recently presented findings from ECOG-ACRIN Cancer Research Group & PrECOG Cancer Research Group #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/3YI9raZ #BreastCancer #Leukemia #Lymphoma

What happens when #ResearchFunding slows? A new analysis looks at stalled studies, delayed discoveries, and the challenges researchers face navigating uncertainty. Read more: bit.ly/44FKmRI #NIH

ICYMI: Watch Joseph A. Sparano, MD, FACP discuss initial findings from a public-private partnership between ECOG-ACRIN & Caris Life Sciences to improve recurrence risk assessment in early-stage #BreastCancer using #ArtificialIntelligence. Video via MedPage Today: bit.ly/48R3uNN #bcsm #AI #SABCS25

Support for collaborative, federally funded #CancerResearch remains essential. The NCI Director Dr. Tony Letai shares his perspective on sustaining this work in a conversation with The Cancer Letter. Read the interview: bit.ly/3Mzqnhd

ECOG-ACRIN, Caris present breast cancer recurrence and risk stratification AI tools (@eaonc.bsky.social) https://cancerletter.com/clinical-roundup/20251212_6a/

Attending #SABCS25 this week? View this helpful guide to @eaonc.bsky.social research at the meeting, including data from an exciting TAILORx correlative science initiative. More: bit.ly/4iTDohN #BreastCancer #bcsm

New analysis of 10 ECOG-ACRIN Cancer Research Group trials shows that for Black #AML patients, survival advantage typically linked to certain mutations (like NPM1) doesn’t hold—highlighting a need to rethink how genetic risk factors are applied across racial groups. More: bit.ly/4pqT92h #ASH25

Attending #ASH25 this weekend? Don't miss the initial results from the myeloMATCH #PrecisionMedicine trial. More info on these exciting updates can be found here: dctd.cancer.gov/about/news-e...

#FindingsFriday: A new analysis of E3805/CHAARTED by Abhishek Tripathi, MD & colleagues shows long-term outcomes for men with metastatic #ProstateCancer may be tied to PSA levels early in treatment. Could offer hope and better planning. More: bit.ly/4oL80n7

At #ASH2025, ECOG-ACRIN & @precogonc.bsky.social researchers will present data that could improve treatments for #AML, #ALL, #MCL, #CLL and more. View our full guide to the meeting: bit.ly/4rtkbHp #BloodCancer #leukemia #lymphoma

The NCI myeloMATCH precision medicine trial portfolio in myeloid cancers is highlighted in numerous presentations at the upcoming #ASH25 meeting. Learn more: dctd.cancer.gov/about/news-e... @swog.org @eaonc.bsky.social @cctg.bsky.social #NCORP

On #WorldPancreaticCancerDay 💜 we are shining a light on two @eaonc.bsky.social clinical trials aiming to improve outcomes for patients with #PancreaticCancer & #PancreaticCysts - EA2185 and EA2192/APOLLO. Learn more here 👉 bit.ly/pancreaticf25

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona, aims to find out. More: bit.ly/EA7211 #leiomyosarcoma #liposarcoma

#FindingsFriday: New insights from the CHAARTED trial, presented at #ASTRO25 - the APUC-6 signature (six androgen production/uptake & conversion genes) may help stratify metastatic #ProstateCancer & refine treatment response. Learn more: bit.ly/43SaV5t #PrecisionMedicine

ICYMI, fascinating finding from #ESMO2025: patients with #cancer who received mRNA COVID vaccines soon after starting #immunotherapy showed stronger immune responses & improved survival. Read the the publication in @nature.com: bit.ly/3LyoZuF #CancerResearch

#FindingsFriday: ICYMI, at #ESMO25 Dr. Janice Mehnert @nyulangone.bsky.social presented results from the STAMP trial, showing that giving pembro after surgery may help prevent #MerkelCellCarcinoma from spreading to distant organs. Promising progress for this rare #SkinCancer! More: bit.ly/49uM4sa

The recently reported DREAM3R results show that, for pts w/ pleural #mesothelioma, the addition of durvalumab to chemo = higher tumor response—yet survival benefit is unclear. More research is needed. Read about this collab between @precogonc.bsky.social & @togaanz.bsky.social: bit.ly/47Pw02S

After being diagnosed with #PancreaticCancer, Steven Merlin found hope through a #clinicaltrial. Now as an ECOG-ACRIN advocate, he shares his perspective on the benefits of clinical trials. Read his inspiring story: bit.ly/beatingtheod...

DYK only 17% of US cancer trials are federally funded—yet they’re far more likely to study rare cancers, pediatric cancers, & multimodality treatments? Public funding = innovation where it’s needed most. More: bit.ly/47kYNME #Oncology #CancerResearch @swog.org